165 related articles for article (PubMed ID: 32615570)
41. Cancer-Associated Fibroblasts Induce Proliferation and Therapeutic Resistance to Everolimus in Neuroendocrine Tumors through STAT3 Activation.
Amin T; Viol F; Krause J; Fahl M; Eggers C; Awwad F; Schmidt B; Benten D; Ungefroren H; Fraune C; Clauditz TS; Sauter G; Izbicki JR; Lohse AW; Huber S; Schrader J
Neuroendocrinology; 2023; 113(5):501-518. PubMed ID: 36473454
[TBL] [Abstract][Full Text] [Related]
42. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
[TBL] [Abstract][Full Text] [Related]
43. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.
Berardi R; Torniai M; Pusceddu S; Spada F; Ibrahim T; Brizzi MP; Antonuzzo L; Ferolla P; Panzuto F; Silvestris N; Partelli S; Ferretti B; Freddari F; Gucciardino C; Testa E; Concas L; Murgioni S; Bongiovanni A; Zichi C; Riva N; Rinzivillo M; Brunetti O; Giustini L; Di Costanzo F; Delle Fave G; Fazio N; De Braud F; Falconi M; Cascinu S
Cancer Med; 2017 Jul; 6(7):1493-1499. PubMed ID: 28547856
[TBL] [Abstract][Full Text] [Related]
44. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
[TBL] [Abstract][Full Text] [Related]
45. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
46. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
47. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract][Full Text] [Related]
48. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.
Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W
Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841
[No Abstract] [Full Text] [Related]
49. Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.
Fujishita T; Kojima Y; Kajino-Sakamoto R; Taketo MM; Aoki M
Oncogene; 2017 Nov; 36(46):6480-6489. PubMed ID: 28759045
[TBL] [Abstract][Full Text] [Related]
50. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
51. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Hofving T; Arvidsson Y; Almobarak B; Inge L; Pfragner R; Persson M; Stenman G; Kristiansson E; Johanson V; Nilsson O
Endocr Relat Cancer; 2018 Mar; 25(3):367-380. PubMed ID: 29444910
[TBL] [Abstract][Full Text] [Related]
52. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
53. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Mateo J; Heymach JV; Zurita AJ
Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
[TBL] [Abstract][Full Text] [Related]
54. Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
Ozkan E; Soydal C; Ucak Semirgin S; Yapici O; Atmaca A; Demirag G
Clin Nucl Med; 2016 Jul; 41(7):561-3. PubMed ID: 27163457
[TBL] [Abstract][Full Text] [Related]
55. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
[TBL] [Abstract][Full Text] [Related]
56. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.
Lee L; Ito T; Igarashi H; Ueda K; Fujiyama T; Kawabe K; Ogawa Y
J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):95-102. PubMed ID: 27926987
[TBL] [Abstract][Full Text] [Related]
57. Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors.
Ciołczyk-Wierzbicka D; Gil D; Laidler P
Med Oncol; 2017 Dec; 35(1):7. PubMed ID: 29214525
[TBL] [Abstract][Full Text] [Related]
58. BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells.
Wang L; Matkar S; Xie G; An C; He X; Kong X; Liu X; Hua X
Cancer Biol Ther; 2017 Apr; 18(4):229-236. PubMed ID: 28281917
[TBL] [Abstract][Full Text] [Related]
59. Kinome rewiring during acquired drug resistance in neuroendocrine neoplasms.
Gérard C; Lagarde M; Poizat F; Oziel-Taieb S; Garcia V; Roche C; Niccoli P; Barlier A; Romano D
Endocr Relat Cancer; 2021 Jan; 28(1):39-51. PubMed ID: 33112824
[TBL] [Abstract][Full Text] [Related]
60. Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors.
Carbonnaux M; Molin Y; Souquet PJ; Tantin A; Lombard-Bohas C; Walter T
Invest New Drugs; 2014 Dec; 32(6):1308-10. PubMed ID: 25119297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
